ESSA Pharma Inc (NASDAQ:EPIX) Short Interest Update

ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 89,000 shares, an increase of 11.4% from the August 30th total of 79,900 shares. Currently, 0.9% of the company’s shares are sold short. Based on an average daily trading volume, of 35,700 shares, the days-to-cover ratio is presently 2.5 days.

Separately, ValuEngine lowered ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 10th.

Shares of EPIX stock traded down $0.01 during trading hours on Wednesday, reaching $3.43. The company’s stock had a trading volume of 11,200 shares, compared to its average volume of 18,159. The stock has a market capitalization of $48.45 million, a P/E ratio of -1.35 and a beta of 1.90. ESSA Pharma has a one year low of $1.41 and a one year high of $4.50. The firm’s fifty day simple moving average is $2.98 and its 200 day simple moving average is $2.54. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 2.27.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.52) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.02. As a group, equities research analysts forecast that ESSA Pharma will post -1.52 earnings per share for the current fiscal year.

About ESSA Pharma

ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Featured Story: What are no-load funds?

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.